SKI7 Antibody

What is SKI7 and what are its primary biological functions?

SKI7 is a multifunctional protein initially identified in Saccharomyces cerevisiae that plays critical roles in RNA metabolism. It functions as a cofactor in both normal mRNA turnover and non-stop mRNA decay (NSD) surveillance pathways . Additionally, SKI7 works as an antiviral protein by negatively controlling the copy number of L-A and M double-stranded RNA viruses in yeast .

The protein exhibits structural similarities to translation factors, particularly Hbs1p and EF1-α, suggesting its evolutionary relationship to translational machinery . This structural homology is functionally relevant as SKI7 represses the expression of non-polyadenylated mRNAs, whether capped or uncapped, which explains its ability to inhibit the propagation of yeast viruses whose mRNAs lack poly(A) tails .

In molecular terms, SKI7 appears to function as a signal-coupling factor between multi-protein complexes operating in the 3'-to-5' mRNA-decay pathway, connecting the exosome with the Ski complex to facilitate efficient RNA degradation .

How is SKI7 structured and what are the functions of its distinct domains?

SKI7 consists of two major structural regions with differentiated functions:

• N-terminal region (Ski7 N): This domain mediates protein-protein interactions with both the Ski complex and the exosome. Specifically:

  • The amino acid sequence 1-96 binds to the Ski complex (as demonstrated through Ski2p-Myc and Ski8p-HA binding assays)

  • Two distinct sequences (80-184 and 168-264) can independently associate with the exosome (shown through Rrp4p-Myc and Ski6p-HA binding)

• C-terminal region (Ski7 C): This domain contains G-protein motifs that are structurally similar to those found in translational GTPases. While Ski7 C does not exhibit GTP-hydrolyzing activities under normal conditions, mutations in this domain can cause specific dysfunction in non-stop decay pathways .

The coordination between these domains is essential for SKI7's function, as demonstrated by experiments showing that the molecular functions of Ski7 C are only effective when present with Ski7 N in the full-length form .

How does SKI7 interact with other protein complexes in mRNA surveillance pathways?

SKI7 serves as a bridging molecule between different multi-protein complexes involved in RNA metabolism:

• Interaction with the exosome: Through specific regions in its N-terminal domain, SKI7 physically associates with exosome components including Rrp4p and Ski6p (also known as Rrp41p) . Gel filtration experiments show SKI7 behaving as part of a complex larger than 300 kDa, suggesting its integration into the exosome machinery .

• Interaction with the Ski complex: SKI7 binds to the Ski complex (comprising Ski2p, Ski3p, and Ski8p) through a distinct N-terminal region (residues 1-96) . This interaction is functionally significant as demonstrated by the observation that overexpression of this binding region alone inhibits 3'-to-5' mRNA decay .

• Competition with Hbs1/Dom34: SKI7's C-terminal region participates in mRNA surveillance in a regulatory manner that competes with the Hbs1/Dom34 complex . Genetic experiments show that when wild-type SKI7 is overexpressed in hbs1Δ or dom34Δ reporter strains, a dominant-negative effect on NSD is observed, suggesting these factors share functional sites on the ribosome .

These interactions collectively enable SKI7 to coordinate the recruitment and activity of RNA degradation machinery at sites of translational stalling or termination.

What are the principal experimental applications for SKI7 antibodies in molecular biology research?

SKI7 antibodies serve as invaluable tools for investigating various aspects of RNA quality control mechanisms:

• Protein-protein interaction studies: SKI7 antibodies enable the detection and characterization of interactions between SKI7 and components of the exosome and Ski complex. Co-immunoprecipitation experiments with epitope-tagged SKI7 variants (SKI7/N and SKI7/Full) have successfully pulled down Rrp4p-Myc and Ski6p-HA, confirming the physical association of SKI7 with the exosome complex .

• Domain mapping: By utilizing antibodies against different SKI7 domains, researchers can map the regions responsible for specific interactions. For example, immunoprecipitation assays with Flag-tagged variants of SKI7/N have identified distinct binding regions for the Ski complex (amino acids 1-96) and the exosome (sequences 80-184 or 168-264) .

• Functional analysis of mutations: Antibodies recognizing specific SKI7 mutants have helped elucidate how mutations affect protein function. For instance, the F207A mutant in Ski7 N represents the first single amino acid loss-of-function mutation reported for SKI7, causing significant stabilization of non-stop mRNA .

• Expression level monitoring: SKI7 antibodies can track protein expression levels under different conditions or in various mutant backgrounds, providing insights into regulatory mechanisms controlling SKI7 abundance and activity.

What methodological considerations are important when designing experiments with SKI7 antibodies?

When designing experiments using SKI7 antibodies, researchers should consider several critical factors:

• Antibody specificity validation: Prior to experimental use, antibodies should be validated for specificity using:

  • Western blot comparison between wild-type and ski7Δ strains

  • Immunoprecipitation followed by mass spectrometry to confirm target identity

  • Expression of epitope-tagged versions of SKI7 as positive controls

• Experimental controls:

  • Include ski7Δ strains as negative controls

  • Use strains expressing epitope-tagged SKI7 variants (as done with Ski7p/N and Ski7p/Full constructs) to confirm antibody specificity

  • When studying dominant-negative effects, compare results in the presence and absence of wild-type SKI7 on the chromosome

• Technical approach selection:

  • For studying SKI7 interactions, co-immunoprecipitation with antibodies against SKI7 or its binding partners proves effective

  • For functional studies, genetic approaches using reporter systems (such as histidine auxotrophic growth) can complement biochemical analyses

  • Gel filtration chromatography can help determine if SKI7 exists in larger complexes (>300 kDa) as previously observed

• Expression system considerations:

  • When overexpressing SKI7, verify that the constructs rescue the phenotype of SKI7-disruption strains to ensure physiological relevance

  • For studies of dominant-negative mutants, use appropriate expression vectors (such as p414GPD) to achieve desired expression levels

How can researchers differentiate between the roles of SKI7's N-terminal and C-terminal domains in mRNA surveillance?

To dissect the distinct functions of SKI7's domains, researchers can employ several strategic approaches:

• Domain-specific mutation analysis:

  • Generate mutations in conserved motifs within each domain separately

  • In the N-terminal domain, the F207A mutation has proven particularly informative, exhibiting significant loss of NSD function

  • For the C-terminal domain, mutations like G279D, S281F, S281P, and L284P in the G-domain have demonstrated dominant-negative effects on NSD

• Domain deletion experiments:

  • Express truncated versions containing only Ski7 N or Ski7 C

  • Compare phenotypes with full-length constructs to assess functional contributions

  • Note that the molecular functions operated by critical Ski7 C residues are only effective in the full-length form, suggesting interdomain coordination

• Competitive interaction studies:

  • Overexpress specific SKI7 domains to competitively inhibit endogenous interactions

  • The sequence 1-96 (Ski complex-binding region) and sequence 80-264 (exosome-binding regions) have been shown to significantly inhibit 3'-to-5' mRNA decay when overexpressed

• Genetic background manipulation:

  • Examine the effects of SKI7 domain mutations in strains lacking interacting partners

  • The dominant-negative effect of Ski7 C mutants (particularly S281P) is strikingly enhanced in hbs1Δ or dom34Δ genetic backgrounds, revealing functional relationships between these factors

What experimental approaches best reveal SKI7's role in the competitive regulation of mRNA surveillance with the Hbs1/Dom34 complex?

The competitive relationship between SKI7 and the Hbs1/Dom34 complex in mRNA surveillance can be investigated through:

• Genetic interaction analyses:

  • Create strains with combinations of mutations in SKI7, HBS1, and DOM34

  • Test for synthetic phenotypes that suggest functional relationships

  • The enhanced dominant-negative effect of Ski7 C mutants (especially S281P) in hbs1Δ or dom34Δ backgrounds provides strong evidence for competitive interactions

• Overexpression studies:

  • Express wild-type or mutant SKI7 in various genetic backgrounds

  • Monitor effects on NSD efficiency using reporter systems

  • Wild-type SKI7 overexpression produces a dominant-negative effect on NSD in hbs1Δ or dom34Δ reporter strains, suggesting competition for ribosomal binding sites

• Ribosome association experiments:

  • Perform polysome profiling with tagged versions of SKI7 and Hbs1/Dom34

  • Compare ribosome association patterns in various genetic backgrounds

  • Assess whether SKI7 and Hbs1/Dom34 bind to similar ribosomal sites or complexes

• Biochemical competition assays:

  • Develop in vitro systems with purified components

  • Test whether increasing concentrations of one factor (SKI7 or Hbs1/Dom34) affect the binding or activity of the other

  • Quantify binding affinities to determine the molecular basis for competition

What are the most reliable methodologies for measuring the impact of SKI7 mutations on non-stop mRNA decay efficiency?

Several complementary approaches provide robust assessment of how SKI7 mutations affect NSD pathways:

• Reporter-based growth assays:

  • Use histidine auxotrophic growth reporters (as in the YWH-1 system)

  • Compare growth on plates lacking histidine as a proxy for NSD efficiency

  • This method effectively identified functional defects in both Ski7 N mutants (F207A) and various Ski7 C mutants (G279D, S281F, etc.)

• mRNA stability measurements:

  • Quantify non-stop mRNA levels using quantitative PCR (qPCR)

  • The stabilization of non-stop HIS3 mRNA in the F207A mutant was confirmed using this approach

  • For more comprehensive analysis, transcriptome-wide approaches like RNA-seq can identify global effects on NSD substrates

• Translation efficiency measurement:

  • Electroporate luciferase mRNAs with different characteristics (capped/uncapped, polyadenylated/non-polyadenylated)

  • Compare luciferase expression levels between wild-type and ski7 mutant strains

  • This approach revealed that ski7 mutation increases both the initial rate and duration of expression of non-poly(A) mRNAs

• Viral propagation assays:

  • Monitor copy numbers of L-A and M double-stranded RNA viruses

  • Overexpression of Ski7p can efficiently cure the satellite virus M2 due to increased repression of non-poly(A) mRNA expression

  • The superkiller phenotype of ski7 mutants provides a convenient readout for defects in viral mRNA repression

How should researchers address contradictory results when studying SKI7 using antibody-based methods?

When facing contradictory results in SKI7 antibody studies, consider these systematic troubleshooting approaches:

• Antibody validation reassessment:

  • Verify antibody specificity through western blotting comparing wild-type and ski7Δ strains

  • Confirm epitope accessibility in different experimental conditions

  • Consider that different antibodies may recognize distinct conformational states of SKI7

• Experimental condition evaluation:

  • SKI7's interactions with the Ski complex and exosome are condition-dependent

  • Different buffer conditions may affect complex stability during immunoprecipitation

  • Temperature sensitivity should be considered, as ski mutations confer cold sensitivity for growth on cells carrying M dsRNA

• Genetic background considerations:

  • Verify the complete genotype of strains used, as SKI7 functions within the broader SKI2-SKI3-SKI8 antiviral system

  • A single ski7 mutation derepresses non-poly(A) mRNA expression similarly to a quadruple ski2 ski3 ski7 ski8 mutant, suggesting genetic interactions

  • Results may vary depending on the presence/absence of viral elements in laboratory strains

• Data interpretation framework:

  • Consider the dual functionality of SKI7 in both normal mRNA turnover and surveillance pathways

  • Distinguish between direct effects on SKI7 and indirect effects via interacting partners

  • Remember that overexpression phenotypes may differ from loss-of-function phenotypes due to dominant-negative effects

What controls are essential when performing immunoprecipitation experiments with SKI7 antibodies?

Robust immunoprecipitation experiments with SKI7 antibodies require these essential controls:

• Negative controls:

  • Perform parallel immunoprecipitations from ski7Δ strains

  • Include isotype-matched irrelevant antibodies as precipitation controls

  • Use beads-only controls to identify non-specific binding

• Input controls:

  • Always analyze total lysate (input) alongside immunoprecipitated samples

  • Quantify the percentage of target protein recovered to assess efficiency

  • Verify equal loading across experimental conditions

• Expression verification:

  • Confirm comparable expression levels of SKI7 variants being studied

  • As demonstrated for truncated Ski7 C mutants, cellular expression levels should be verified to be comparable to wild-type

• Interaction specificity controls:

  • Test for co-precipitation of known interactors (Ski2p, Ski8p, Rrp4p, Ski6p) as positive controls

  • Include unrelated abundant proteins as negative controls for non-specific binding

  • When studying new interactions, confirm reciprocal co-immunoprecipitation if possible

• Functional validation:

  • Verify that expression constructs rescue the phenotype of SKI7-disruption strains

  • For dominant-negative studies, confirm that effects are nullified in Ski7 C-only forms

How can researchers accurately interpret SKI7 antibody data in relation to drug sensitivity phenotypes?

The interpretation of SKI7 antibody data in conjunction with drug sensitivity requires careful consideration:

• Hygromycin B sensitivity analysis:

  • ski7 mutants exhibit hypersensitivity to hygromycin B, suggesting a role in translation

  • When correlating antibody-detected SKI7 levels with drug sensitivity:

    • Prepare serial dilutions (e.g., OD600 of 0.15, 0.015, 0.0015) of wild-type and ski7 cells

    • Spot equal volumes on media with or without hygromycin B (100 μg/ml)

    • Compare growth patterns between strains with different SKI7 expression levels or mutations

• Comparative analysis framework:

  • Create a systematic comparison table correlating:

    • SKI7 expression levels (quantified by western blot)

    • Mutation status (wild-type, point mutations, deletions)

    • Growth on hygromycin B and cycloheximide

    • mRNA decay efficiency measurements

• Functional domain correlation:

  • Determine which SKI7 domains are required for drug resistance

  • Map mutations affecting drug sensitivity to specific functional regions

  • Correlate antibody-detected conformational changes with altered drug sensitivity

• Integration with other phenotypic data:

  • Combine drug sensitivity data with other functional readouts (mRNA stability, viral propagation)

  • Create integrated models explaining how SKI7's various functions relate to translation and drug resistance

  • Consider that SKI7's effects on non-poly(A) mRNA expression may indirectly affect drug sensitivity through altered gene expression patterns

What are promising approaches for developing more specific SKI7 antibodies for studying domain-specific functions?

Advancing SKI7 antibody development could involve:

• Structural epitope mapping:

  • Utilize the known binding regions of SKI7 to design epitope-specific antibodies

  • Target the Ski complex-binding region (amino acids 1-96) or exosome-binding regions (80-184 and 168-264) with high specificity

  • Develop antibodies recognizing specific conformational states that occur during different functional interactions

• Antibody engineering techniques:

  • Apply computational antibody design methods similar to those used with RFdiffusion for antibody structure prediction

  • Fine-tune antibodies for improved specificity using structure-guided approaches

  • Develop single-domain antibodies (VHHs) that can access epitopes not available to conventional antibodies

• Validation strategy development:

  • Create comprehensive panels of SKI7 mutants for antibody validation

  • Establish standardized protocols for confirming antibody specificity across different experimental conditions

  • Develop quantitative metrics for antibody performance in various applications

How might SKI7 antibodies be employed to investigate potential roles of SKI7 beyond currently established functions?

SKI7 antibodies could reveal unexplored functions through:

• Novel interaction partner identification:

  • Perform immunoprecipitation followed by mass spectrometry under various cellular stress conditions

  • Investigate SKI7 associations during viral infection, oxidative stress, or nutrient limitation

  • Compare interactomes between wild-type SKI7 and specific domain mutants

• Subcellular localization studies:

  • Use immunofluorescence to track SKI7 localization under different conditions

  • Examine potential associations with stress granules, P-bodies, or other RNA processing bodies

  • Correlate localization changes with functional states using specific antibodies

• Post-translational modification analysis:

  • Develop modification-specific antibodies (phospho-SKI7, ubiquitinated-SKI7)

  • Map how modifications affect SKI7's interactions with the exosome, Ski complex, or ribosomes

  • Investigate whether SKI7 modifications serve as regulatory switches between different functional states

• Evolutionary conservation investigation:

  • Use cross-reactive antibodies to study SKI7 homologs across species

  • Examine functional conservation of domain-specific interactions in different organisms

  • Investigate how SKI7's roles may have expanded or specialized throughout evolution